AAS
CPRX

Ameritas Advisory Services’s Catalyst Pharmaceutical CPRX Stock Holding History

Ameritas Advisory Services’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-15,596
Closed -$386K – 1984
2026
Q1 		$386K Buy
+15,596
New +$372K 0.02% 669
2023
Q1 		– Sell
-58,599
Closed -$1.09M – 2721
2022
Q4 		$1.09M Buy
+58,599
New +$902K 0.05% 328

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameritas Advisory Services's CPRX Position: Q2 2026 in Review

Ameritas Advisory Services sold out of Catalyst Pharmaceutical (CPRX) in Q2 2026, closing a stake of 15,596 shares — an estimated $386K sold.

Ameritas Advisory Services first reported a position in CPRX in Q4 2022 and held it in 2 quarters. The position peaked at $1.09M in Q4 2022. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Ameritas Advisory Services reported no remaining Catalyst Pharmaceutical position as of Q2 2026 after selling out during the quarter.
  • Ameritas Advisory Services sold 15,596 Catalyst Pharmaceutical shares in Q2 2026, an estimated $386K.
  • Ameritas Advisory Services first reported a position in Catalyst Pharmaceutical in Q4 2022 and held it in 2 quarters.
  • Ameritas Advisory Services's Catalyst Pharmaceutical position peaked at $1.09M in Q4 2022.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Ameritas Advisory Services's 13F filing for Q2 2026, filed 14 Aug 2026.